AstraZeneca Ultomiris gets approval in EU to treat rare neuromuscular disorder

Retrieved on: 2022-09-23 08:34:27

Tags for this article:

Organ systems

Branches of biology

Nervous system

Quaternary ammonium compounds

RTT

GMG

Neuromuscular junction

Acetylcholine receptor

Paroxysmal nocturnal hemoglobinuria

Click the tags to see associated articles and topics

AstraZeneca Ultomiris gets approval in EU to treat rare neuromuscular disorder. View article details on HISWAI: https://seekingalpha.com/news/3885521-astrazeneca-ultomiris-gets-approval-in-eu-to-treat-rare-neuromuscular-disorder%3Fsource%3Dcontent_type%253Areact%257Cfirst_level_url%253Amarket-news%257Csection_asset%253Atrending%257Csection%253Aus-economy

Excerpt

The European Commission ((EC)) approved the expanded use of AstraZeneca's (AZN) Ultomiris (ravulizumab) as an add-on to standard therapy for adult ...

Article found on: seekingalpha.com

View Original Article